The microbiome therapies pipeline features 260 drugs under evaluation across different phases of development

Manufacturing live biotherapeutic products is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs.

Key Inclusions

• A detailed review of the overall landscape of companies offering contract services for manufacturing of microbiome therapeutics, including information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, type of service(s) offered (strain isolation, media / culture development, fermentation, lyophilization, fill / finish, cell banking, and analytical services), type of  product manufactured (active pharmaceutical ingredients (API) and finished drug formulations (FDF)), type of drug molecule (small molecules and biologics / live biotherapeutics (LBPs)), type of fermentation (aerobic and anaerobic), type of formulation (solids (tablets / capsules / powders / granules), oral liquids (syrups and solutions), injectables and others), type of primary packaging used (ampoules / vials, blister packing, glass / plastic bottles, pouches / sachets, and others), number and location of manufacturing facilities (country-wise), facility size (if available), as well as their certifications, and company's contact details.
• A list of companies with in-house manufacturing facilities for microbiome therapeutics along with information on year of establishment, company size, scale of operations (preclinical, clinical and commercial), location of headquarters, and location of manufacturing facilities (country-wise).
• Elaborate profiles of key industry players (large and mid-sized companies, established before 2000) based in North America, Europe and Asia-Pacific that offer contract manufacturing services for microbiome therapeutics at both clinical and commercial scales. Each profile features a brief overview of the company, microbiome-related service portfolio, information on microbiome manufacturing facilities (if available), and recent developments and an informed future outlook.
• An assessment of microbiome contract manufacturing capability in different regions, based on a number of relevant parameters, such as number of CMOs, number of completed / active / planned clinical trials, number of patients enrolled, number of manufacturing facilities, number of companies offering API / FDF manufacturing, number of companies having capabilities for preclinical / clinical / commercial manufacturing, number of companies dedicated to aerobic / anaerobic fermentation, installed manufacturing capacity, and number of in-house players.

A list of nearly 50 microbiome-focused drug developers that are anticipated to partner with contract manufacturers and have been shortlisted on the basis of parameters, such as developer strength (which takes into account the company's size and its experience in this field), company's pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and the availability of in-house manufacturing capabilities

To order this 300+ page report, which features 140+ figures and 125+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html

The USD 300 million (by 2030) financial opportunity within the microbiome contract manufacturing market has been analysed across the following segments:

• Type of Product Manufactured
• Active Pharmaceutical Ingredients (APIs)
• Finish Drug Formulations (FDFs)

• Type of Type of Formulation
• Solid Formulations
• Oral Liquids
• Injectables
• Others

• Scale of Operation
• Clinical
• Commercial

• Company Size
• Small-sized
• Mid-sized
• Large

• Key Geographical Regions
• North America
• Europe
• Asia-Pacific and Rest of the World

The Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, report features the following companies, which we identified to be key players in this domain:

• Bristol Myers Squibb
• GlaxoSmithKline
• Incyte
• Novartis
• Trillium Therapeutics

Table of Contents

1. Preface

2. Executive Summary

3. Introduction
 

4. Market Landscape
 

5. Company Profiles
 

6. Regional Capability Analysis
 

7. Likely Partner Analysis
 

8. Clinical Trial Analysis
 

9. Capacity Analysis
 

10. Demand Analysis
 

11. Make versus Buy Decision Making Framework
 

12. Microbiome related initiatives of Big Pharmaceutical Players
 

13. Market Forecast
 

14. Conclusion

15. Executive Insights

16. Appendix 1: Tabulated Data

17. Appendix 2: List of Companies and Organizations

18. Appendix 3: List of Probiotic Supplement Contract Manufacturers and       

Microbial Contract Service Providers

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]